Tempus AI Director Nadja West Sells 3,000 Shares for $207,000

A top executive at Tempus AI, the artificial intelligence company racing to transform cancer treatment and clinical decision-making, has begun quietly offloading her stake in the company just months after its blockbuster debut, raising questions about insider confidence at a moment when AI-driven healthcare startups face intense scrutiny over their clinical claims. Nadja West's sale of 3,000 shares—a relatively modest transaction on its surface—carries outsized significance in a sector where every executive move is parsed by investors and competitors hungry for signals about whether the technology truly delivers on its transformative promises.

The Motley Fool·Sep 2